Silvio Danese
Appearances
- DateMay 8, 2023This session presents the best submitted clinical abstracts as determined by their specific council sections…
Presenter
- DateMay 7, 2023Background: Resolution of intestinal inflammation requires well-tuned communication between the immune compartment and the epithelium, carried out primarily via secreted mediators. The expression of these mediators is predominantly regulated by the transcription factor NF-κB…
Presenter
Speakers
Humanitas University - DateMay 9, 2023BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Presenter
Northwestern Feinberg School of MedicineSpeakers
Icahn School of Medicine at Mount Sinai - DateMay 9, 2023BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Presenter
Speakers
Icahn School of Medicine, Mount SinaiSwedish Medical CenterWestern UniversityKatholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven - DateMay 9, 2023BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…
Presenter
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven - DateMay 9, 2023BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…
Presenter
Cedars-Sinai Medical Center - DateMay 7, 2023Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Presenter
Speakers
University of Chicago Division of the Biological SciencesWestern UniversityCedars-Sinai Medical Center - DateMay 20, 2024BACKGROUND: Risankizumab (RZB), an anti-interleukin 23p19 monoclonal antibody, demonstrated efficacy for moderately to severely active ulcerative colitis (UC) in the 12-week phase 3 INSPIRE induction study (NCT03398148)…
- DateMay 20, 2024BACKGROUND: Disease clearance in ulcerative colitis (UC) is defined as concurrent achievement of clinical, endoscopic, and histologic remission…
Presenter
Western UniversitySpeakers
Icahn School of Medicine at Mount SinaiKatholieke Universiteit Leuven Universitaire Ziekenhuizen LeuvenWestern University - DateMay 21, 2024BACKGROUND: The primary objective of the VIVID-1 trial (NCT03926130) was to demonstrate efficacy and safety of mirikizumab (miri), a p19-directed anti-IL-23 antibody, compared to placebo (PBO) in patients (pts) with moderate-to-severe Crohn’s disease…
Presenter
Speakers
Mayo ClinicCharité - Universitätsmedizin BerlinWestern University - DateMay 21, 2024BACKGROUND: VTX002 is a novel oral selective sphingosine-1-phosphate-1 (S1P1) receptor modulator in development for the treatment of ulcerative colitis (UC)…
Presenter
Speakers
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven - DateMay 21, 2024Obefazimod is an investigational, oral, once-daily, small molecule which enhances expression of microRNA-124 and is currently in phase 3 clinical trials for the treatment of patients with moderately to severely active ulcerative colitis (UC) [1]…
Presenter
Katholieke Universiteit Leuven Universitaire Ziekenhuizen LeuvenSpeakers
Icahn School of Medicine, Mount SinaiNorthwestern University Feinberg School of MedicineCharité - Universitätsmedizin Berlin
